<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146848</url>
  </required_header>
  <id_info>
    <org_study_id>CR-CA-100604-H</org_study_id>
    <secondary_id>PEGASUS</secondary_id>
    <nct_id>NCT00146848</nct_id>
  </id_info>
  <brief_title>PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy</brief_title>
  <acronym>PEGASUS CRT</acronym>
  <official_title>Pacing Evaluation - Atrial Support Study in Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at different pacing modes (how a device is programmed to pace one's
      heart), and how these modes may assist in one's daily activities and how one is feeling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PEGASUS CRT is a multicenter trial that will assess the effect of a cardiac resynchronization
      therapy defibrillator (CRT-D) device programmed to DDD-70 or DDDR-40 compared to a CRT device
      programmed to DDD-40 in heart failure patients. The effect of atrial support pacing in heart
      failure patients will be assessed using a clinical composite rating. A sub-study will
      evaluate the effect pacing mode has on exercise capacity in this heart failure population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Composite Score</measure>
    <time_frame>From randomization (6-weeks) through 12-month visit</time_frame>
    <description>The primary outcome measure classified patients as improved, unchanged or worsened, based on a 4 components clinical composite score using the following four components: death, heart failure hospitalization, New York Heart Association [NYHA] class, patient's Global Assessment rating. Best value is improved, whereas worst value is worsened.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>From randomization (6-weeks) through 12-month visit</time_frame>
    <description>Quality of Life as assessed by the Minnesota Living with Heart Failure Questionniare for those patients with paired data at 6 weeks and 12 months. This score is on a scale of 0(best)- 105(worst). A negative change denotes improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self Assessed Physical Activity</measure>
    <time_frame>From randomization (6-weeks) through 12-month visit</time_frame>
    <description>Physical activity was assessed using the Physical Activity Scale of the Elderly (PASE) questionnaire for those patients with paired data available at the 6 week and 12 month visits. The PASE is designed to assess physical activity in older persons. The total PASE score was computed by multiplying the amount of time spent in each activity (hours/week) or participation (yes/no) in an activity by empirically derived item weights and summing over all activities. PASE scores for this study ranged from 0 to 756 with higher scores indicating more physical activity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1742</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>DDD-40</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DDD-40 for this trial is the comparator arm. Even though patients are receiving a CRT-D device, atrial support pacing in this arm will be limited as the device will not pace unless the rate falls below 40 bpm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DDDR-40</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DDDR-40 programming will initiate atrial support pacing if the rate falls below 40 bpm or if atrial support is needed in response to increased activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DDD-70</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atrial support pacing in this arm will be delivered when the rate falls below 70 bpm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices</intervention_name>
    <description>All subjects in this trial receive the same device. For the purpose of this trial, &quot;intervention&quot; is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm.</description>
    <arm_group_label>DDD-40</arm_group_label>
    <arm_group_label>DDDR-40</arm_group_label>
    <arm_group_label>DDD-70</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet current indications for the CONTAK RENEWALÂ® family of cardiac
             resynchronization therapy defibrillator (CRT-D) devices or future Food and Drug
             Administration (FDA) approved Guidant CRT-D devices

          -  Patients who sign and date a Patient Informed Consent at, or prior to, the implant
             visit

          -  Patients who are in sinus rhythm at the time of implant

          -  Patients who remain in the clinical care of the enrolling physician in approved
             centers

          -  Patients who are on optimal pharmacologic therapy or who have developed a recent
             implantable cardioverter defibrillator (ICD) indication that necessitates ICD therapy
             concurrent with the optimization of pharmacologic therapy

        Exclusion Criteria:

          -  Patients whose medical condition is expected to preclude the use of the
             protocol-required pacing mode (dual chamber pacing [DDD or DDDR]) and respective lower
             rate limits

          -  Patients with permanent atrial fibrillation or atrial flutter

          -  Patients who are in complete heart block

          -  Patients who have previously had a pacemaker, ICD, or CRT device

          -  Patients whose life expectancy is less than 12 months due to other medical conditions

          -  Patients who are expected to receive a heart transplant during the duration of the
             study

          -  Patients who have other cardiac surgeries or procedures planned but not yet performed

          -  Patients who currently have or who are likely to receive a tricuspid valve prosthesis

          -  Patients who are currently enrolled in another investigational study or registry that
             would directly impact the treatment or outcome of the current study.

          -  Patients who are younger than 18 years of age

          -  Patients who are mentally incompetent and cannot sign a Patient Informed Consent form
             or comply with the study

          -  Patients who are or become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David O. Martin, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Day</last_name>
    <role>Principal Investigator</role>
    <affiliation>Utah Heart Clinic, LDS Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cleveland Clinic Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Martin DO, Stolen KQ, Brown S, Yu Y, Christie C, Doshi SK, Smith JM, Gold MR, Day JD. Pacing Evaluation-Atrial SUpport Study in Cardiac Resynchronization Therapy (PEGASUS CRT): design and rationale. Am Heart J. 2007 Jan;153(1):7-13.</citation>
    <PMID>17174627</PMID>
  </reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>February 28, 2010</results_first_submitted>
  <results_first_submitted_qc>September 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2010</results_first_posted>
  <last_update_submitted>December 20, 2011</last_update_submitted>
  <last_update_submitted_qc>December 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment began on November 8, 2004, was completed on December 21, 2007, with study follow-up commencing January 30, 2009. This trial was conducted at institutional settings throughout the United States and Australia.</recruitment_details>
      <pre_assignment_details>All patients with successful system implants were programmed to DDD-40 (atrial rate support above 40 bpm; limited atrial pacing) for the first 6-weeks of the trial. Randomization (1:1:1 allocation) occurred after patients had reached the 6-week visit and continued to meet all of the eligibility criteria for the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DDD-40</title>
          <description>Atrial Tracking (atrial rate support above 40 bpm)</description>
        </group>
        <group group_id="P2">
          <title>DDD-70</title>
          <description>Atrial Rate Support (atrial rate support above 70 bpm)</description>
        </group>
        <group group_id="P3">
          <title>DDDR-40</title>
          <description>Rate Adaptive Pacing (atrial rate support above 40 bpm with rate responsive pacing)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre-randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1742">Registered</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1433">Reached 6-week visit and were randomized</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
                <participants group_id="P2" count="488"/>
                <participants group_id="P3" count="470"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="441"/>
                <participants group_id="P3" count="431"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DDD-40</title>
          <description>Atrial Tracking (atrial rate support above 40 bpm)</description>
        </group>
        <group group_id="B2">
          <title>DDD-70</title>
          <description>Atrial Rate Support (atrial rate support above 70 bpm)</description>
        </group>
        <group group_id="B3">
          <title>DDDR-40</title>
          <description>Rate Adaptive Pacing (atrial rate support above 40 bpm with rate responsive pacing)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="475"/>
            <count group_id="B2" value="488"/>
            <count group_id="B3" value="470"/>
            <count group_id="B4" value="1433"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="11.4"/>
                    <measurement group_id="B2" value="67.5" spread="10.4"/>
                    <measurement group_id="B3" value="66.7" spread="11.6"/>
                    <measurement group_id="B4" value="67.2" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="332"/>
                    <measurement group_id="B3" value="305"/>
                    <measurement group_id="B4" value="947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life</title>
        <description>Quality of Life as assessed by the Minnesota Living with Heart Failure Questionniare for those patients with paired data at 6 weeks and 12 months. This score is on a scale of 0(best)- 105(worst). A negative change denotes improvement.</description>
        <time_frame>From randomization (6-weeks) through 12-month visit</time_frame>
        <population>Quality of Life was analyzed for those patients with paired data available at the 6 week and 12 month visit. Patients were analyzed in their randomized groups.</population>
        <group_list>
          <group group_id="O1">
            <title>DDD-40</title>
            <description>Atrial Tracking (atrial rate support above 40 bpm)</description>
          </group>
          <group group_id="O2">
            <title>DDD-70</title>
            <description>Atrial Rate Support (atrial rate support above 70 bpm)</description>
          </group>
          <group group_id="O3">
            <title>DDDR-40</title>
            <description>Rate Adaptive Pacing (atrial rate support above 40 bpm with rate responsive pacing)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life</title>
          <description>Quality of Life as assessed by the Minnesota Living with Heart Failure Questionniare for those patients with paired data at 6 weeks and 12 months. This score is on a scale of 0(best)- 105(worst). A negative change denotes improvement.</description>
          <population>Quality of Life was analyzed for those patients with paired data available at the 6 week and 12 month visit. Patients were analyzed in their randomized groups.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" spread="24.18"/>
                    <measurement group_id="O2" value="-3.27" spread="22.77"/>
                    <measurement group_id="O3" value="-4.46" spread="25.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The changes in quality of life were compared between groups using two-sided t-tests.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.14</ci_lower_limit>
            <ci_upper_limit>3.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The difference in changes in quality of life between groups were compared using a t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>5.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Composite Score</title>
        <description>The primary outcome measure classified patients as improved, unchanged or worsened, based on a 4 components clinical composite score using the following four components: death, heart failure hospitalization, New York Heart Association [NYHA] class, patient's Global Assessment rating. Best value is improved, whereas worst value is worsened.</description>
        <time_frame>From randomization (6-weeks) through 12-month visit</time_frame>
        <population>This analysis is intention to treat (ITT) in terms of patient's being analyzed according to their randomized group. Last observation carried forward (LOCF) method was used for missing NYHA and global assessment measures at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>DDD-40</title>
            <description>Atrial Tracking (atrial rate support above 40 bpm)</description>
          </group>
          <group group_id="O2">
            <title>DDD-70</title>
            <description>Atrial Rate Support (atrial rate support above 70 bpm)</description>
          </group>
          <group group_id="O3">
            <title>DDDR-40</title>
            <description>Rate Adaptive Pacing (atrial rate support above 40 bpm with rate responsive pacing)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Composite Score</title>
          <description>The primary outcome measure classified patients as improved, unchanged or worsened, based on a 4 components clinical composite score using the following four components: death, heart failure hospitalization, New York Heart Association [NYHA] class, patient's Global Assessment rating. Best value is improved, whereas worst value is worsened.</description>
          <population>This analysis is intention to treat (ITT) in terms of patient's being analyzed according to their randomized group. Last observation carried forward (LOCF) method was used for missing NYHA and global assessment measures at 12 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="441"/>
                <count group_id="O3" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="235"/>
                    <measurement group_id="O3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One sided test testing for shift towards improvement in either atrial support pacing treatment arm compared to the DDD-40 arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Cochran-Armitage test for trend</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Cochran-Armitage test for trend</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self Assessed Physical Activity</title>
        <description>Physical activity was assessed using the Physical Activity Scale of the Elderly (PASE) questionnaire for those patients with paired data available at the 6 week and 12 month visits. The PASE is designed to assess physical activity in older persons. The total PASE score was computed by multiplying the amount of time spent in each activity (hours/week) or participation (yes/no) in an activity by empirically derived item weights and summing over all activities. PASE scores for this study ranged from 0 to 756 with higher scores indicating more physical activity.</description>
        <time_frame>From randomization (6-weeks) through 12-month visit</time_frame>
        <population>Physical activity was assessed using the Physical Activity Scale for the Elderly and was analyzed for those patients with paired data available at the 6 week and 12 month visit. Patients were analyzed in their randomized groups. Postive values for changes denote improvements.</population>
        <group_list>
          <group group_id="O1">
            <title>DDD-40</title>
            <description>Atrial Tracking (atrial rate support above 40 bpm)</description>
          </group>
          <group group_id="O2">
            <title>DDD-70</title>
            <description>Atrial Rate Support (atrial rate support above 70 bpm)</description>
          </group>
          <group group_id="O3">
            <title>DDDR-40</title>
            <description>Rate Adaptive Pacing (atrial rate support above 40 bpm with rate responsive pacing)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Self Assessed Physical Activity</title>
          <description>Physical activity was assessed using the Physical Activity Scale of the Elderly (PASE) questionnaire for those patients with paired data available at the 6 week and 12 month visits. The PASE is designed to assess physical activity in older persons. The total PASE score was computed by multiplying the amount of time spent in each activity (hours/week) or participation (yes/no) in an activity by empirically derived item weights and summing over all activities. PASE scores for this study ranged from 0 to 756 with higher scores indicating more physical activity.</description>
          <population>Physical activity was assessed using the Physical Activity Scale for the Elderly and was analyzed for those patients with paired data available at the 6 week and 12 month visit. Patients were analyzed in their randomized groups. Postive values for changes denote improvements.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="362"/>
                <count group_id="O3" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.45" spread="78.62"/>
                    <measurement group_id="O2" value="22.62" spread="88.86"/>
                    <measurement group_id="O3" value="25.69" spread="92.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Compare the difference in the changes in physical activity scores between groups using a t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.65</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Compare the difference in the changes in physical activity scores between groups using a t-test.
To adjust for multiple comparisons, an alpha level of 0.025 should be used to deem significance.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.11</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from randomization (6-weeks) through the 12-month follow-up visit. Per trial design, serious adverse events were not collected in this trial.</time_frame>
      <desc>Source vocabulary for AE coding was not used in this trial. Serious adverse events were not collected in this trial per trial design.</desc>
      <group_list>
        <group group_id="E1">
          <title>DDD-40</title>
          <description>Atrial Tracking (atrial rate support above 40 bpm)</description>
        </group>
        <group group_id="E2">
          <title>DDD-70</title>
          <description>Atrial Rate Support (atrial rate support above 70 bpm)</description>
        </group>
        <group group_id="E3">
          <title>DDDR-40</title>
          <description>Rate Adaptive Pacing (atrial rate support above 40 bpm with rate responsive pacing)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="488"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular related</sub_title>
                <counts group_id="E1" events="124" subjects_affected="80" subjects_at_risk="475"/>
                <counts group_id="E2" events="125" subjects_affected="89" subjects_at_risk="488"/>
                <counts group_id="E3" events="117" subjects_affected="76" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-device, non-lead, non-procedure or non-cardiovascular related AE &quot;other&quot;</sub_title>
                <counts group_id="E1" events="82" subjects_affected="64" subjects_at_risk="475"/>
                <counts group_id="E2" events="58" subjects_affected="43" subjects_at_risk="488"/>
                <counts group_id="E3" events="54" subjects_affected="45" subjects_at_risk="470"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lack of longer-term follow-up. Single blind design where investigator could be aware of treatment assignment. Two conservative atrial support pacing modes; results should not be extended to substantially more atrial pacing and higher heart rates.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kira Stolen</name_or_title>
      <organization>Clinical Affairs</organization>
      <phone>1 800 CARDIAC</phone>
      <email>cshd@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

